Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.
Wolf, Chen … Kim
JAMA Ophthalmol·Apr 23, 2026
The CONDOR trial demonstrated that brolucizumab 6mg was superior to panretinal photocoagulation (PRP) in preserving visual acuity and achieving PDR regression at 54 weeks, with 63.6% of brolucizumab patients showing no PDR versus 22.4% with PRP.
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.
Shah, Makwana … Ramsey
Am J Ophthalmol·Apr 21, 2026
In patients with type 2 diabetes and diabetic retinopathy, GLP-1 receptor agonist use was associated with reduced risk of both systemic vascular complications and ocular complications including progression to proliferative diabetic retinopathy, retinal vein occlusions, and neovascular glaucoma.
Vision-Related Quality of Life in Geographic Atrophy: Association with Topographic Lesion Distribution.
Anegondi, Lam … Wu
Ophthalmology·Apr 22, 2026
In patients with bilateral geographic atrophy, vision-related quality of life is most strongly associated with GA extent within the central 2.5-mm diameter region around the fovea, explaining 11% of variance in visual function scores.
Impact of Phacoemulsification on Neovascular Age-Related Macular Degeneration Activity: Predictive Role of Choroidal Vascularity and MNV Subtypes.
Cha, Youn … Choi
Retina·Apr 21, 2026
Cataract surgery increases neovascular AMD treatment requirements in 45.2% of patients, with higher preoperative choroidal vascularity index and PCV subtype serving as predictive risk factors for increased post-surgical anti-VEGF needs.
Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry.
Goncalves, Hashimoto … Gabrielle
Ophthalmol Retina·Apr 20, 2026
Treatment-naive neovascular AMD eyes experiencing 6-12 month visit gaps during anti-VEGF therapy showed significant visual decline of nearly 5 letters immediately after the gap. Visit gaps occurred in 25% of eyes by 6.5 years, highlighting the importance of consistent monitoring schedules.
CRVO, BRVO, retinal ischemia, macular edema from RVO
Takayasu Retinopathy Findings on Ultra-Wide Field Fundus Fluorescein Angiography.
Sharma, Parmar … Singh
Ocul Immunol Inflamm·Apr 24, 2026
Ultra-widefield fundus fluorescein angiography (UWF-FFA) detected more advanced Takayasu retinopathy than conventional 7-field imaging in 52.6% of eyes, leading to treatment decisions in 35.9% of cases that would have been missed otherwise.
Risk Factors for Ocular Complications in Pediatric Uveitis: Analysis of 133 Cases from a Retrospective Single-Center Study.
Karaca, Ersoy … Esen
Ocul Immunol Inflamm·Apr 25, 2026
In this retrospective study of 133 pediatric non-infectious uveitis patients, low baseline visual acuity was the only independent predictor of ocular complications, with posterior synechiae being the most common complication (53.4% of patients).
Utility of the Collaborative Ocular Tuberculosis Study (COTS) calculator in the management of a case of frosted branch angiitis secondary to presumed intraocular tuberculosis - a case report.
Yin, Ali … Sen
J Ophthalmic Inflamm Infect·Apr 23, 2026
Abstract not available — see full article for details.
Immune Mediators in Birdshot Chorioretinopathy: A Systematic Review.
Gao, Zaslavsky … Derzko-Dzulynsky
Ocul Immunol Inflamm·Apr 23, 2026
This systematic review of 14 studies identifies Th17-mediated inflammation as the primary immune mechanism in birdshot chorioretinopathy, with elevated intraocular IL-17, systemic IL-21/IL-23, and expansion of CD8+ T-cells and NK cells driving disease pathogenesis.
A 16-year-old boy with bilateral APMPPE and granulomatous anterior uveitis was found to have previously undiagnosed Crohn's disease, achieving complete remission with systemic corticosteroids and anti-TNFα therapy.
Neuroretinitis: Etiologies, Treatment Approaches, and Visual Outcomes from a Tertiary Referral Center.
Çam, Altintas & Celiker
Ocul Immunol Inflamm·Apr 20, 2026
This retrospective study of 21 patients with neuroretinitis found Bartonella henselae was the most common etiology (42.9%), with excellent visual outcomes achieved through individualized treatment including empirical antibiotics and systemic corticosteroids.
Adalimumab Therapy as a Rescue Treatment Option in Refractory Acute Sympathetic Ophthalmia: Case Series and Review of Literature.
Narain, Gupta … Rath
Ocul Immunol Inflamm·Apr 20, 2026
Adalimumab demonstrated rapid efficacy in controlling inflammation and exudative retinal detachment in three patients with acute sympathetic ophthalmia refractory to conventional immunosuppressive therapy.